Researchers Find a Better Way to Save Eyesight in Third-world Countries

Study finds low-cost eye drops equal in effectiveness to more costly antibiotics

Bacterial keratitis, an infection of the cornea often caused by contact lenses, malnutrition, or an injury, can lead to corneal scarring, one of the leading causes of blindness around the globe, according to the World Health Organization. It has blinded more than 400,000 children worldwide.

LA BioMed Celebrates the Accomplishments of Three “Legends”

Nov. 15 Event to Honor Outstanding Physician-Researchers

In a continuation of a tradition for recognizing its most outstanding physician-researchers, LA BioMed will celebrate the many accomplishments of Drs. Sherwin J. Isenberg, Nora C.J. Sun and Ronald S. Swerdloff on Nov. 15 at Legends 2016 at the Torrance Marriott Redondo Beach.  

Long-term oxygen treatment does not benefit some COPD patients

Study addresses long-standing question for those with moderately low blood oxygen levels

Newly published data from the Long-Term Oxygen Treatment Trial (LOTT) show that oxygen use is not beneficial for most people with chronic obstructive pulmonary disease (COPD) and moderately low levels of blood oxygen.

LA BioMed Study Seeks to Improve Diabetic Eye Health

Researchers find Divergent Views on Barriers to Diabetic Retinopathy Screening

LOS ANGELES – (Oct. 10, 2016) – While diabetes is the most common cause of blindness in the working-age population in the U.S., only about 55% of lower income adults living with the disease undergo the retinal screening needed to detect and help prevent blindness.

LA County Supervisors Approve Funding for LA BioMed to Help Stimulate Region’s Biosciences Industry

Funding to Help Create Incubator on Institute’s Campus to Help New Businesses Thrive

LOS ANGELES – (Oct. 4, 2016) – The Los Angeles County Board of Supervisors unanimously approved $3 million in funding today to help pay for the creation of a biosciences incubator on LA BioMed’s campus that will provide technical support and business services to help researchers bring promising new discoveries to market so the public can benefit from them.

California Life Sciences Association Partners with LA BioMed and Lab Launch to Grow World-Class Life Sciences Innovation Hub in Los Angeles; Opens Los Angeles Office

Alliances to Strengthen Los Angeles County’s Life Sciences Community

California Life Sciences Association (CLSA), the nation’s largest statewide public policy and business leadership organization representing California’s leading life sciences innovators, today announced new strategic partnerships with LA BioMed and Lab Launch, and the unveiling of its Los Angeles satellite office, to regularly engage and bolster Los Angeles County’s life sciences community.

New Chief Scientific Officer Joins LA BioMed

Dr. Joaquín Madrenas Brings Decades of Research Experience to the Institute

Further strengthening its research enterprise, LA BioMed announced today the addition of a new chief scientific officer to its leadership team, Joaquín (Quim) Madrenas, MD, PhD. Dr. Madrenas brings decades of experience as a researcher, physician, educator and administrator to one of the nation’s leading nonprofit independent research institutes.

Higher ICU Usage Led to Increased Invasive Procedures and Costs

New Study of Four Common Conditions Finds ICU Use Didn’t Improve Mortality Rates

LOS ANGELES – With the use of intensive care units (ICUs) on the rise in many hospitals, researchers at LA BioMed and UCLA examined ICU usage and found patients who were admitted to these units underwent more costly and invasive procedures but didn’t have better mortality rates than hospitalized patients with the same medical conditions who weren’t admitted to the ICU.

Two Classes of Medications Associated with Similar Reduction In Cardiovascular Risk in Peritoneal Dialysis Patients

New Study Finds ARB and ACEI Linked to Similar Results

LOS ANGELES – With cardiovascular disease being the No. 1 cause of death in end-stage kidney disease patients on peritoneal dialysis, a new study examined two classes of medications commonly prescribed to prevent cardiovascular events in these patients and found no significant difference in outcomes.

Creative Medical Technologies Licenses Patient-Specific Adult Stem Cell Therapy for Male Infertility

Clinical Stage Adult Stem Cell Company Expands Portfolio of Clinical Indications

Creative Medical Technologies, Inc. (CMT) announced today the signing of a license agreement with LA BioMed granting exclusive rights for United States patent application # 14/508763, covering the use of stem cells for treatment of male infertility.  In the patent application and a subsequent publication,[1] Ronald S.